- Thrombosis drugs, designed to prevent or treat blood clot formation, are becoming increasingly essential in modern healthcare settings for managing conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation patients, due to their life-saving potential and role in reducing long-term complications
- The surging demand for thrombosis drugs is primarily driven by the rising global incidence of cardiovascular diseases, expanding geriatric population, sedentary lifestyles, and growing awareness regarding early intervention and preventative care
- North America dominated the thrombosis drug market with the largest revenue share of 39.1% in 2024, attributed to advanced healthcare infrastructure, high awareness levels, favorable reimbursement policies, and the presence of leading pharmaceutical manufacturers actively engaged in R&D for novel anticoagulants
- Asia-Pacific is expected to be the fastest growing region in the thrombosis drug market during the forecast period due to increasing healthcare expenditure, improving diagnostic capabilities, and a growing burden of cardiovascular diseases
- Oral segment dominated the thrombosis drug market with a market share of 56.3% in 2024, driven by its patient preference for non-invasive options and the growing adoption of DOACs that do not require regular monitoring, thereby improving compliance and treatment outcomes
